U.S. Markets closed

AnaptysBio, Inc. (ANAB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
24.97+0.48 (+1.96%)
At close: 4:00PM EDT
25.00 +0.03 (0.12%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close24.49
Open24.57
Bid24.09 x 800
Ask24.16 x 800
Day's Range23.95 - 25.54
52 Week Range13.92 - 35.85
Volume336,630
Avg. Volume275,098
Market Cap683.364M
Beta (5Y Monthly)0.05
PE Ratio (TTM)N/A
EPS (TTM)-0.73
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.80
  • AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference
    GlobeNewswire

    AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference

    SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 1:30 p.m. ET. The conference will be conducted virtually, and the audio presentation will be available via: https://wsw.com/webcast/jeff174/anab/1811646. A live webcast of the presentation will also be available through the investor section of the AnaptysBio website at https://ir.anaptysbio.com/events. A replay of the webcast will be available for 60 days following the event. About AnaptysBio AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. The Company’s proprietary anti-inflammatory pipeline includes imsidolimab, its anti-IL-36R antibody, previously referred to as ANB019, for the treatment of dermatological inflammatory diseases, including generalized pustular psoriasis, or GPP, EGFRi skin toxicity, ichthyosis, hidradenitis suppurativa and acne; its anti-PD-1 agonist program, ANB030, for treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated; and its BTLA modulator program, ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. AnaptysBio’s antibody pipeline has been developed using its proprietary somatic hypermutation, or SHM platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology collaboration with GSK, including an anti-PD-1 antagonist antibody (JEMPERLI (dostarlimab-gxly)), an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889) and an anti-LAG-3 antagonist antibody (GSK4074386), and an inflammation collaboration with Bristol-Myers Squibb, including an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in clinical development. Contact:Dennis MulroyAnaptysBio, Inc.858.732.0201dmulroy@anaptysbio.com

  • Forecast: Analysts Think AnaptysBio, Inc.'s (NASDAQ:ANAB) Business Prospects Have Improved Drastically
    Simply Wall St.

    Forecast: Analysts Think AnaptysBio, Inc.'s (NASDAQ:ANAB) Business Prospects Have Improved Drastically

    AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders will have a reason to smile today, with the analysts making substantial...

  • AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates
    Zacks

    AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates

    AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 7.04% and -1.45%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?